Latest Biotech News

GlaxoSmithKline agreed to acquire 35Pharma for $950 million in cash to obtain HS‑235, a protein‑based candidate aimed at pulmonary arterial hypertension (PAH) and related pulmonary hypertensive...

Novo Nordisk struck a multi‑hundred‑million to multi‑billion dollar collaboration with Vivtex to accelerate oral delivery of peptide and protein therapeutics, committing up to roughly $2.1 billion...

Novo Nordisk announced a plan to cut U.S. list prices for its GLP‑1 drugs by up to 50% starting in 2027 while simultaneously releasing midstage data showing its triple‑agonist delivered roughly...

Beam Therapeutics launched BEAM‑304, a liver‑targeted base editing program designed to correct prevalent PAH gene mutations that cause phenylketonuria (PKU), and plans IND filings in 2026. The...

Regulators ordered a pause in patient enrollment in MacroGenics’ Phase 2 oncology trial after a patient death and multiple life‑threatening adverse events were reported. The FDA placed a partial...

Researchers at The Jackson Laboratory, the Broad Institute and Yale mapped the regulatory activity of more than 220,000 single‑nucleotide variants across five human cell types using a massively...

A Northwestern University team described heterobifunctional proteomimetic polymers (HYDRACs) that bind disordered oncogenic proteins like MYC and KRAS and recruit cellular degradation machinery,...

Lex Diagnostics began commercial rollout of the Velo point‑of‑care molecular PCR system after FDA 510(k) clearance and a CLIA waiver for its flu/COVID assay; the cartridge‑based platform delivers...

Astellas Pharma and Vir Biotechnology struck a global co‑development and co‑commercialization pact around Vir’s PRO‑XTEN masked T‑cell engager program, centered on the prostate cancer candidate...

Novo Nordisk agreed to a collaboration with Vivtex to develop oral peptide and protein formulations, in a deal that could reach up to $2.1 billion in upfront, R&D and milestone payments plus...

GSK agreed to acquire 35Pharma for $950 million in cash to obtain HS‑235, a protein‑based candidate targeting the activin receptor signaling pathway for pulmonary hypertension (PH). The...

The U.S. Food and Drug Administration ordered a freeze on enrollment in MacroGenics’ Phase 2 trial following a patient death and multiple life‑threatening adverse events. The agency’s action...

Beam Therapeutics announced a liver‑targeted base‑editing program, BEAM‑304, designed to correct prevalent PAH gene mutations that cause phenylketonuria (PKU). Beam plans to pursue multiple...

Researchers at Northwestern reported HYDRACs—heterobifunctional proteomimetic polymers that recruit cellular degradation machinery to remove previously “undruggable” oncoproteins such as MYC and...

Ultima Genomics struck an agreement with Hamilton to automate sample preparation and amplification workflows on Hamilton’s Microlab Star platform, supporting scale‑up of Ultima’s high‑throughput...

The Advanced Research Projects Agency for Health (ARPA‑H) designated up to $144 million for anti‑aging research, funding teams to study markers and interventions for healthy longevity and...

UC‑Davis researchers introduced Chromatin HiFi (CiFi), a protocol combining chromatin conformation capture with PacBio HiFi long reads to generate richer, long‑range chromatin interaction maps and...

A study published in Science linking the gut microbiome to the efficacy of PD‑1 immunotherapy in epithelial tumors has been awarded the Bial Award in Biomedicine and its €350,000 prize. The work...

Novo Nordisk signed a collaboration and licensing agreement with Vivtex that could total up to $2.1 billion in payments to develop oral formulations of peptide and protein therapies for obesity,...

GSK agreed to acquire 35Pharma for $950 million in cash to secure HS-235, a protein‑based candidate poised for pulmonary hypertension (PH) studies, the companies said. HS‑235 completed a Phase I...